JP4331206B2 - ペリンドプリルおよびその薬学的に許容され得る塩の、新規な合成方法 - Google Patents
ペリンドプリルおよびその薬学的に許容され得る塩の、新規な合成方法 Download PDFInfo
- Publication number
- JP4331206B2 JP4331206B2 JP2006524395A JP2006524395A JP4331206B2 JP 4331206 B2 JP4331206 B2 JP 4331206B2 JP 2006524395 A JP2006524395 A JP 2006524395A JP 2006524395 A JP2006524395 A JP 2006524395A JP 4331206 B2 JP4331206 B2 JP 4331206B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- synthesis method
- perindopril
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims description 12
- 229960002582 perindopril Drugs 0.000 title claims description 10
- 150000003839 salts Chemical class 0.000 title claims description 5
- 238000001308 synthesis method Methods 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- YERWBBMSDMSDKT-UHFFFAOYSA-N ethyl 2-oxopentanoate Chemical compound CCCC(=O)C(=O)OCC YERWBBMSDMSDKT-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- FDMGPVBOWQRJCK-HNNXBMFYSA-N benzyl (2s)-2,3,4,5,6,7-hexahydro-1h-indole-2-carboxylate Chemical compound O=C([C@H]1NC2=C(CCCC2)C1)OCC1=CC=CC=C1 FDMGPVBOWQRJCK-HNNXBMFYSA-N 0.000 description 2
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FZONPMWWFYVPPU-GWCFXTLKSA-N (2S)-1-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]-2,3,4,5,6,7-hexahydroindole-2-carboxylic acid Chemical compound C1CCCC2=C1N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C)[C@H](C(O)=O)C2 FZONPMWWFYVPPU-GWCFXTLKSA-N 0.000 description 1
- NRAMCLOSUDJHAH-YUMQZZPRSA-N (2s)-2-[[(2s)-1-ethoxy-1-oxopropan-2-yl]amino]pentanoic acid Chemical compound CCC[C@@H](C(O)=O)N[C@@H](C)C(=O)OCC NRAMCLOSUDJHAH-YUMQZZPRSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- -1 K 2 CO 3 Chemical class 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ARGCRCXTJMQKNA-KKUMJFAQSA-N benzyl (2s,3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indole-2-carboxylate Chemical compound O=C([C@H]1N[C@H]2CCCC[C@H]2C1)OCC1=CC=CC=C1 ARGCRCXTJMQKNA-KKUMJFAQSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- SDBQPOCLUYDXKE-YFKPBYRVSA-N tert-butyl n-[(2s)-1-chloro-1-oxopropan-2-yl]carbamate Chemical compound ClC(=O)[C@H](C)NC(=O)OC(C)(C)C SDBQPOCLUYDXKE-YFKPBYRVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
で示される化合物を、S立体配置を有する、式(III):
で示される化合物と、塩基の存在下で反応させて、アミノ官能の脱保護化の後に、式(IV):
で示される化合物を得て、これを、炭素上のパラジウムの存在下、水素圧の下で、2−オキソペンタン酸エチルと反応させて、式(I)で示される化合物を直接に得ることを特徴とする方法に関するものである。
工程A:(2S)−1−{(2S)−2−[(tert−ブトキシカルボニル)アミノ]プロピオニル}−2,3,4,5,6,7−ヘキサヒドロ−1H−インドール−2−カルボン酸ベンジル
(2S)−2,3,4,5,6,7−ヘキサヒドロ−1H−インドール−2−カルボン酸ベンジル200gおよびジクロロメタン1.5Lを反応器に導入し、次いで、反応混合物の温度を0℃にさせ、トリエチルアミン107ml、次いで、(2S)−2−[(tert−ブトキシカルボニル)アミノ]プロピオニル クロリド162gを加える。次いで、混合物を周囲温度にさせる。この温度で1時間撹拌した後、混合物を、水、次いで、希酢酸溶液で洗浄する。そうして得られる(2S)−1−{(2S)−2−[(tert−ブトキシカルボニル)アミノ]プロピオニル}−2,3,4,5,6,7−ヘキサヒドロ−1H−インドール−2−カルボン酸ベンジル溶液を、そのまま、次の工程に用いる。
上記工程で得られる溶液を、反応器に導入し、次いで、トリフルオロ酢酸133gを加える。周囲温度で1時間30分撹拌した後、混合物を、水、次いで、炭酸水素ナトリウムの飽和溶液で洗浄し、溶媒を蒸発し、除去して、(2S)−1−{(2S)−2−アミノプロピオニル}−2,3,4,5,6,7−ヘキサヒドロ−1H−インドール−2−カルボン酸ベンジルを得る。
上記工程で得られる化合物200gおよびエタノール溶液中の2−オキソペンタン酸エチル88gを水素化容器に導入し、次いで、10%Pd/C5gを導入する。大気圧下、30℃で、理論量の水素が吸収されるまで、水素化をする。濾過によって触媒を除去し、次いで、溶媒を蒸発し、除去する。これによって、(2S,3aS,7aS)−1−{(2S)−2−[(1S)−1−(エトキシカルボニル)ブチルアミノ]プロピオニル}オクタヒドロ−1H−インドール−2−カルボン酸を、85%の収率で得る。
上記工程で得られる化合物(200g)を、アセトニトリル2.8Lに溶解し、次いで、tert−ブチルアミン40gおよび酢酸エチル0.4Lを加える。次いで、得られる懸濁液を、溶解が完了するまで還流し、次いで、得られる溶液を、熱間濾過し、15〜20℃の温度まで、撹拌しつつ冷却する。得られる沈澱を、濾取し、アセトニトリルで再びペーストにさせ、乾燥し、次いで、酢酸エチルから再結晶させて、予期される生成物を、95%の収率および99%の鏡像異性体純度で得る。
Claims (6)
- 式(II)および(III)示される化合物間の反応に用いられる塩基が、トリエチルアミン、ピリジン、N−メチルモルホリンおよびジイソプロピルエチルアミンから選ばれる有機アミン、またはNaOH、KOH、Na2CO3、K2CO3、NaHCO3またははKHCO3のような無機塩基であることを特徴とする、請求項1記載の合成方法。
- 水素化反応をアルコール性溶媒中で実施することを特徴とする、請求項1または2のいずれかに記載の合成方法。
- 水素化反応を1〜5バールの圧力下で実施することを特徴とする、請求項1〜3のいずれか一項に記載の合成方法。
- 水素化反応を20〜60℃の温度で実施することを特徴とする、請求項1〜4のいずれか一項に記載の合成方法。
- そのtert−ブチルアミン塩の形態のペリンドプリルを合成するための、請求項1〜5のいずれか一項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03292132A EP1380591B1 (fr) | 2003-08-29 | 2003-08-29 | Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
PCT/FR2004/002197 WO2005023842A1 (fr) | 2003-08-29 | 2004-08-27 | Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007526902A JP2007526902A (ja) | 2007-09-20 |
JP4331206B2 true JP4331206B2 (ja) | 2009-09-16 |
Family
ID=29724624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006524395A Expired - Fee Related JP4331206B2 (ja) | 2003-08-29 | 2004-08-27 | ペリンドプリルおよびその薬学的に許容され得る塩の、新規な合成方法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7534896B2 (ja) |
EP (1) | EP1380591B1 (ja) |
JP (1) | JP4331206B2 (ja) |
CN (1) | CN100383160C (ja) |
AR (1) | AR045516A1 (ja) |
AT (1) | ATE310012T1 (ja) |
AU (1) | AU2004270428B2 (ja) |
DE (1) | DE60302287T2 (ja) |
DK (1) | DK1380591T3 (ja) |
EA (1) | EA008668B1 (ja) |
ES (1) | ES2252633T3 (ja) |
HK (1) | HK1096408A1 (ja) |
MY (1) | MY136638A (ja) |
NZ (1) | NZ545336A (ja) |
PL (1) | PL211508B1 (ja) |
SI (1) | SI1380591T1 (ja) |
WO (1) | WO2005023842A1 (ja) |
ZA (1) | ZA200601429B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1371659B1 (fr) * | 2003-08-29 | 2005-10-12 | Les Laboratoires Servier | Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
ES2314583T4 (es) | 2005-01-06 | 2009-05-18 | Ipca Laboratories Limited | Proceso para sintesis de los derivados del acido (2s,3as,7as)-1-(s)-alanil-octahidro-1h-indol-2-carboxilico y su utilizacion en la sintesis de perindropil. |
WO2009157018A2 (en) * | 2008-06-24 | 2009-12-30 | Matrix Laboratories Ltd | Novel polymorphic forms of perindopril (l)-arginine and process for the preparation thereof |
WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
JP6753699B2 (ja) * | 2016-05-27 | 2020-09-09 | ミネベアミツミ株式会社 | 転がり軸受 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1321471T3 (da) | 2003-03-12 | 2005-08-29 | Servier Lab | Ny syntesefremgangsmåde til perindopril og farmaceutisk acceptable salte heraf |
DK1319668T3 (da) * | 2003-03-12 | 2005-02-14 | Servier Lab | Fremgangsmåde til syntese af (2S, 3aS, 7aS)-1-((S)-alanyl)-octahydro-1H-indol-2-carboxylsyrederivater og anvendelse heraf ved syntese af perindopril |
DK1367061T3 (da) * | 2003-06-30 | 2006-05-15 | Servier Lab | Fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf |
EP1371659B1 (fr) * | 2003-08-29 | 2005-10-12 | Les Laboratoires Servier | Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
ES2272922T3 (es) * | 2003-08-29 | 2007-05-01 | Les Laboratoires Servier | Nuevo procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables. |
DE60311942T2 (de) * | 2003-11-19 | 2007-12-06 | Les Laboratoires Servier | Verfahren für die Synthese von Perindopril und seiner pharmazeutischen annehmbaren Salzen |
-
2003
- 2003-08-29 AT AT03292132T patent/ATE310012T1/de active
- 2003-08-29 EP EP03292132A patent/EP1380591B1/fr not_active Expired - Lifetime
- 2003-08-29 SI SI200330124T patent/SI1380591T1/sl unknown
- 2003-08-29 ES ES03292132T patent/ES2252633T3/es not_active Expired - Lifetime
- 2003-08-29 DK DK03292132T patent/DK1380591T3/da active
- 2003-08-29 DE DE60302287T patent/DE60302287T2/de not_active Expired - Lifetime
-
2004
- 2004-08-26 MY MYPI20043495A patent/MY136638A/en unknown
- 2004-08-27 CN CNB2004800235355A patent/CN100383160C/zh not_active Expired - Fee Related
- 2004-08-27 NZ NZ545336A patent/NZ545336A/en not_active IP Right Cessation
- 2004-08-27 EA EA200600454A patent/EA008668B1/ru not_active IP Right Cessation
- 2004-08-27 JP JP2006524395A patent/JP4331206B2/ja not_active Expired - Fee Related
- 2004-08-27 US US10/569,537 patent/US7534896B2/en not_active Expired - Fee Related
- 2004-08-27 PL PL379628A patent/PL211508B1/pl unknown
- 2004-08-27 ZA ZA200601429A patent/ZA200601429B/en unknown
- 2004-08-27 AU AU2004270428A patent/AU2004270428B2/en not_active Ceased
- 2004-08-27 WO PCT/FR2004/002197 patent/WO2005023842A1/fr active Application Filing
- 2004-08-27 AR ARP040103079A patent/AR045516A1/es not_active Application Discontinuation
-
2007
- 2007-02-01 HK HK07101186A patent/HK1096408A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2004270428B2 (en) | 2008-08-21 |
JP2007526902A (ja) | 2007-09-20 |
CN1835966A (zh) | 2006-09-20 |
DE60302287T2 (de) | 2006-08-10 |
US20070010572A1 (en) | 2007-01-11 |
US7534896B2 (en) | 2009-05-19 |
AR045516A1 (es) | 2005-11-02 |
EA008668B1 (ru) | 2007-06-29 |
EA200600454A1 (ru) | 2006-08-25 |
DE60302287D1 (de) | 2005-12-22 |
EP1380591A1 (fr) | 2004-01-14 |
SI1380591T1 (sl) | 2006-02-28 |
EP1380591B1 (fr) | 2005-11-16 |
MY136638A (en) | 2008-11-28 |
ES2252633T3 (es) | 2006-05-16 |
HK1096408A1 (en) | 2007-06-01 |
DK1380591T3 (da) | 2006-01-23 |
PL379628A1 (pl) | 2006-10-30 |
ZA200601429B (en) | 2007-05-30 |
PL211508B1 (pl) | 2012-05-31 |
ATE310012T1 (de) | 2005-12-15 |
CN100383160C (zh) | 2008-04-23 |
WO2005023842A1 (fr) | 2005-03-17 |
NZ545336A (en) | 2009-03-31 |
AU2004270428A1 (en) | 2005-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG107249A (bg) | Метод за синтез на периндоприл и негови фармацевтично приемливи соли | |
JP3868957B2 (ja) | (2S,3aS,7aS)−1−[(S)−アラニル]−オクタヒドロ−1H−インドール−2−カルボン酸化合物の新しい合成方法及びペリンドプリルの合成における応用 | |
JP4377412B2 (ja) | ペリンドプリルおよびその薬学的塩の合成方法 | |
JP4347341B2 (ja) | ペリンドプリル及びその薬学的に許容し得る塩の新規合成方法 | |
JP4331207B2 (ja) | ペリンドプリルおよびその薬学的に許容され得る塩の、新規な合成方法 | |
JP4331205B2 (ja) | ペリンドプリルおよびその薬学的に許容され得るその塩の、新規な合成方法 | |
JP4331206B2 (ja) | ペリンドプリルおよびその薬学的に許容され得る塩の、新規な合成方法 | |
JP4377413B2 (ja) | ペリンドプリルおよび薬学的に許容され得るその塩を合成する方法 | |
JP4279871B2 (ja) | (2s,3as,7as)−1−[(s)−アラニル]−オクタヒドロ−1h−インドール−2−カルボン酸誘導体類を合成する新規な方法およびペリンドプリル合成におけるその使用 | |
JP4263744B2 (ja) | ペリンドプリル及びその薬学的に許容し得る塩の新規な合成方法 | |
JP4563372B2 (ja) | ペリンドプリルおよびその薬理上許容される塩を合成する新規な方法 | |
JP4263743B2 (ja) | ペリンドプリル及びその薬学的に許容し得る塩の新規な合成方法 | |
JP2007537996A (ja) | (2S,3aS,7aS)−1−[(S)−アラニル]オクタヒドロ−1H−インドール−2−カルボン酸の誘導体を合成する方法、およびペリンドプリルの合成のためのその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090609 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090617 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120626 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130626 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130626 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140626 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |